argenex SE (NASDAQ:ARGX) Receives $1,056.89 Consensus Target Price from Analysts

argenex SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-four brokerages that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $1,118.2778.

ARGX has been the topic of several recent research reports. Morgan Stanley boosted their price objective on shares of argenex from $1,200.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Tuesday. Wells Fargo & Company raised their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. Bank of America lifted their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Citizens Jmp increased their price target on shares of argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research report on Tuesday. Finally, Citigroup increased their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st.

argenex Stock Performance

Shares of ARGX stock opened at $1,032.86 on Friday. The stock has a fifty day moving average price of $889.43 and a 200 day moving average price of $824.32. The stock has a market cap of $64.62 billion, a PE ratio of 39.66, a P/E/G ratio of 1.03 and a beta of 0.46. argenex has a 1 year low of $651.89 and a 1 year high of $1,035.09.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. As a group, equities research analysts predict that argenex will post 29.04 earnings per share for the current year.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase 3 data strengthened confidence in efgartigimod’s effectiveness in autoimmune myositis. Analysts said the results reduce development and commercial risk for the VYVGART franchise, potentially creating another significant growth market. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
• Positive Sentiment: Morgan Stanley and Oppenheimer viewed the myositis data as supportive of the VYVGART outlook, with Oppenheimer describing the results as helping “derisk” the opportunity. Argenx’s Myositis Data Derisk Vyvgart Opportunity, Oppenheimer Says
• Positive Sentiment: Several firms raised their valuation targets following the data: Morgan Stanley to $1,230 with an Overweight rating, HC Wainwright to $1,202 with a Buy rating, Wedbush to $1,150, RBC to $1,100, and Truist to $1,095. These revisions signal increased expectations for future earnings and sales growth.
• Positive Sentiment: HC Wainwright increased its EPS forecasts to $34.82 for fiscal 2027 and $44.72 for fiscal 2028, above its prior estimates of $34.38 and $43.50. The higher estimates reflect improving confidence in argenex’s longer-term growth prospects. Piper Sandler Forecasts Strong Price Appreciation for argenex Stock

Institutional Investors Weigh In On argenex

A number of large investors have recently bought and sold shares of the stock. Navellier & Associates Inc. increased its position in argenex by 3.3% during the second quarter. Navellier & Associates Inc. now owns 7,257 shares of the company’s stock worth $6,733,000 after buying an additional 234 shares in the last quarter. Merit Financial Group LLC boosted its stake in shares of argenex by 17.1% during the second quarter. Merit Financial Group LLC now owns 466 shares of the company’s stock valued at $432,000 after acquiring an additional 68 shares during the last quarter. Farther Finance Advisors LLC increased its position in argenex by 9.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 365 shares of the company’s stock worth $338,000 after purchasing an additional 32 shares in the last quarter. Ballentine Partners LLC increased its position in argenex by 30.8% during the 2nd quarter. Ballentine Partners LLC now owns 772 shares of the company’s stock worth $716,000 after purchasing an additional 182 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new position in argenex in the 2nd quarter valued at about $27,584,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.